Evidence map›Paper›PMID 37360441›Full record

ArticleACS omega2023

Functionalized Magnetic Nanoparticles for NIR-Induced Photothermal Therapy of Potential Application in Cervical Cancer.

Linxue Zhang, Gulinigaer Alimu, Zhong Du, Ting Yan, Hui Li, Rong Ma, Zhongwen Lan, Zhong Yu, Nuernisha Alifu, Ke Sun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Linxue ZhangState Key Laboratory of Pathogenesis, Prevention, and Treatment of High Incidence Diseases in Central Asia/School of Medical Engineering and Technology, Xinjiang Medical University, Urumqi 830054, China.ORCID https://orcid.org/0000-0003-3452-2213
Gulinigaer AlimuState Key Laboratory of Pathogenesis, Prevention, and Treatment of High Incidence Diseases in Central Asia/School of Medical Engineering and Technology, Xinjiang Medical University, Urumqi 830054, China.
Zhong DuState Key Laboratory of Pathogenesis, Prevention, and Treatment of High Incidence Diseases in Central Asia/Department of Gynecology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
Ting YanState Key Laboratory of Pathogenesis, Prevention, and Treatment of High Incidence Diseases in Central Asia/School of Medical Engineering and Technology, Xinjiang Medical University, Urumqi 830054, China.
Hui LiState Key Laboratory of Pathogenesis, Prevention, and Treatment of High Incidence Diseases in Central Asia/School of Medical Engineering and Technology, Xinjiang Medical University, Urumqi 830054, China.
Rong MaState Key Laboratory of Pathogenesis, Prevention, and Treatment of High Incidence Diseases in Central Asia/Department of Gynecology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
Zhongwen LanSchool of Materials and Energy, University of Electronic Science and Technology of China, Chengdu 610054, China.
Zhong YuSchool of Materials and Energy, University of Electronic Science and Technology of China, Chengdu 610054, China.
Nuernisha AlifuState Key Laboratory of Pathogenesis, Prevention, and Treatment of High Incidence Diseases in Central Asia/School of Medical Engineering and Technology, Xinjiang Medical University, Urumqi 830054, China.
Ke SunSchool of Materials and Energy, University of Electronic Science and Technology of China, Chengdu 610054, China.
Xinjiang Medical University · CNUniversity of Electronic Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Photothermal therapy (PTT) holds great promise for cancer treatment with its effective ablation of solid tumors. As the essential core point, photothermal agents (PTAs) with excellent photothermal properties and good biocompatibility could help to fulfill highly efficient PTT. Herein, a novel type of nanoplatform Fe

Identifiers

PMID37360441
PMCPMC10286267
OpenAlexW4379792448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.